Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole for Childhood Obsessive-Compulsive Disorder
NCT00251303Phase 2Completed
- Sponsor
- National Institute of Mental Health
- Start
- Aug 2005
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of riluzole in obsessive compulsive disorder (OCD), sponsored by National Institute of Mental Health. Primary endpoint: Clinical Global Impressions - Improvement at 12 weeks. Started Aug 2005; status: completed.
02
Drugs
riluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT00251303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251303.